Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Laekna Therapeutics Shanghai Co. Ltd. currently has 1 pending office action. This action is assigned to 1 distinct examiner, JUEDES, AMY E, who is also identified as the busiest examiner for the portfolio with 1 pending office action. The data shows 0 distinct art units, which may reflect a very early stage of the administrative process or a specific filing status for the current matter.
With only 1 pending office action total, the company's current active prosecution is extremely limited. The outcome of this single matter depends entirely on the review by the 1 distinct examiner involved. Practitioners should focus on the specific requirements and past history of this examiner, as they represent the only active point of contact within the patent office for the company's current portfolio. The absence of a recorded art unit suggests that the prosecution is in a unique or transitional phase.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JUEDES, AMY E | 1 | 44.7% | +41.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18574243 | DEPLETION OF ACTIVATED HEPATIC STELLATE CELLS (HSCS) AND USES THEREOF | JUEDES, AMY E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18574243 | DEPLETION OF ACTIVATED HEPATIC STELLATE CELLS (HSCS) AND USES THEREOF | JUEDES, AMY E | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18574243 | DEPLETION OF ACTIVATED HEPATIC STELLATE CELLS (HSCS) AND USES THEREOF | JUEDES, AMY E | — | §102§103§112 | Non-Final OA | — | Pending | Dec 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLaekna Therapeutics Shanghai Co. Ltd. has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
Amy E Juedes has the most, with 1 of Laekna Therapeutics Shanghai Co. Ltd.'s pending office actions.